Luftschein S, Bienenstock H, Varady J C, Stitt F W
J Rheumatol. 1979 Jul-Aug;6(4):397-404.
A group of 50 patients with rheumatoid arthritis (half of whom received prednisone for 12 weeks before and then during the study) participated in a double-blind trial evaluating the efficacy and safety of 3 dosages of naproxen (125, 250, and 500 mg b.i.d.). Increasing dosages of naproxen were associated with increasing levels of therapeutic response and increasing serum levels of naproxen with no evidence of toxicity. Corticosteroid patients did not exhibit the same pattern of increasing levels of efficacy. The study demonstrates a dosage-related increasing pattern of efficacy for naproxen up to 1,000 mg/day, a pattern not yet demonstrated for the other non-steroidal antinflammatory drugs.
